Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × PM 01183 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 5 Sarcoma, Ewing 3 Sarcoma 3 Endometrial Neoplasms 3 Neoplasms 2 Stomach Neoplasms 1 SCLC, Extensive Stage 1 Recurrence 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Mesothelioma 1 Glioblastoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Desmoplastic Small Round Cell Tumor 1 Colorectal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Dexamethasone 24 Cyclophosphamide 21 venetoclax 17 fludarabine 12 Lenalidomide 12 Bortezomib 12 pembrolizumab 11 Cytarabine 11 Carboplatin 10 Calcium Dobesilate 10 Rituximab 8 pomalidomide 7 Nivolumab 7 Gemcitabine 7 Azacitidine 7 fludarabine phosphate 6 carfilzomib 6 selinexor 5 daratumumab 5 blinatumomab 5 Temozolomide 5 Decitabine 5 Cisplatin 5 Bendamustine Hydrochloride 5 obinutuzumab 4 ibrutinib 4 elotuzumab 4 Methotrexate 4 Etoposide 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04358237 2025-06-04

LUPER

Blanco, Dr Antonio Calles MD

Phase 1/2 Completed

Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡